NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Descending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
43975-0253-14 | 43975-0253 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0254-05 | 43975-0254 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0254-14 | 43975-0254 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0255-05 | 43975-0255 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0255-14 | 43975-0255 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0257-05 | 43975-0257 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0256-05 | 43975-0256 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
43975-0256-14 | 43975-0256 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | July 13, 2016 | In Use | |
00078-0670-66 | 00078-0670 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | July 12, 2016 | Oct. 31, 2024 | In Use |
00179-0212-70 | 00179-0212 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | July 8, 2016 | Dec. 31, 2016 | In Use |
Found 10,000 results in 6 milliseconds — Export these results